The U.S. Food and Drug Administration (FDA) has given positive feedback to Annovis Bio’s plans to start two Phase 3 clinical trials of buntanetap (ANVS401) as an oral therapy for early- and late-stage Parkinson’s disease. The feedback followed a review of data from a Phase 2 clinical trial showing significant…
A first patient in Canada has been dosed in a Phase 1 clinical trial of DA01, a cell-based investigational therapy for advanced Parkinson’s disease by BlueRock Therapeutics. The therapy consists of surgically injecting neurons (nerve cells) that make dopamine — and which are damaged and die with Parkinson’s — into…
A team of scientists at the University of Cincinnati, in Ohio, has received a grant worth $1.2 million from the U.S. Department of Defense (DOD) to study how stress can affect — and worsen the progression of — Parkinson’s disease. The researchers, led by Kim Seroogy, PhD, previously showed…
Iktos is working with Astrogen to use artificial intelligence (AI) to identify small molecules as candidates for the treatment of Parkinson’s disease. Under the collaboration’s terms, Iktos will apply its proprietary machine-learning algorithm to virtually “sketch”molecules directed against a defined target and shortlist candidates for preclinical studies, the companies…
Alembic Pharmaceuticals has received final approval from the U.S. Food and Drug Administration (FDA) for its generic version of entacapone as an add-on therapy for treating end-of-dose “wearing off” in Parkinson’s disease, the company announced. These entacapone tablets are “therapeutically equivalent” to Comtan and treat the motor…
Argobio and GeneCode are teaming up to develop small molecules mimicking glial cell-derived neurotrophic factor (GDNF), a protein that helps nerve cells survive, for the treatment of Parkinson’s and other diseases. The collaboration builds on previous work by researchers at GeneCode, who together with Mart Saarma, PhD,…
A computer software that tracks how facial muscles move during a video selfie may be able to help predict whether a person is likely to develop Parkinson’s disease, a study reported. The study involved the use of the PARK test, a web-based application designed to detect and objectively measure…
A gene therapy targeting the substantia nigra, the brain region with dopamine-producing nerve cells, may boost the benefits of levodopa for people with Parkinson’s disease, a study reports. This idea was tested in a new mouse disease model — one in which Parkinson’s symptoms appeared after disrupting a protein…
Mapping of a brain circuit that is of particular relevance to neurological diseases such as Parkinson’s and Huntington’s revealed key features about its architecture and information flow, a study in mice reported. This brain circuit involves a looping connection between the cortex, the basal ganglia, and the thalamus…
Mission Therapeutics has been awarded a Therapeutic Pipeline Program grant from the Michael J. Fox Foundation for Parkinson’s Research (MJFF) to advance development of its USP30 deubiquitylating enzyme (DUB) inhibitors for the treatment of familial Parkinson’s disease. The grant, worth about $500,000, will be used to test these inhibitors in animals that model…
Get regular updates to your inbox.
